Hennion & Walsh Asset Management, Inc. Exelixis, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.06 Billion
- Q3 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 62,911 shares of EXEL stock, worth $2.16 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
62,911
Previous 68,972
8.79%
Holding current value
$2.16 Million
Previous $1.55 Million
5.36%
% of portfolio
0.08%
Previous 0.08%
Shares
14 transactions
Others Institutions Holding EXEL
# of Institutions
500Shares Held
244MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$1.01 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$874 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$529 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$394 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.1B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...